Hollsteen
← MACOM

Research and development

Flow – sum over the period · $M

QuartersFiscal years

$MResearch and development · Q1 FY2016: $25.0M · 10-Q 0001193125-16-439832 filed Jan 27, 2016Research and development · Q2 FY2016: $26.0M · 10-Q 0001193125-16-559543 filed Apr 27, 2016Research and development · Q3 FY2016: $26.0M · 10-Q 0001493594-16-000007 filed Jul 27, 2016Research and development · Q4 FY2016: $30.0M · derived · 10-K 0001493594-17-000055 filed Nov 15, 2017Research and development · Q1 FY2017: $30.0M · 10-Q 0001493594-17-000012 filed Feb 1, 2017Research and development · Q2 FY2017: $40.0M · 10-Q 0001493594-17-000037 filed Apr 26, 2017Research and development · Q3 FY2017: $39.0M · 10-Q 0001493594-17-000046 filed Aug 2, 2017Research and development · Q4 FY2017: $39.0M · derived · 10-K 0001493594-18-000034 filed Nov 16, 2018Research and development · Q1 FY2018: $42.0M · 10-Q 0001493594-18-000008 filed Feb 7, 2018Research and development · Q2 FY2018: $42.0M · 10-Q 0001493594-18-000019 filed May 3, 2018Research and development · Q3 FY2018: $48.0M · 10-Q 0001493594-18-000026 filed Aug 1, 2018Research and development · Q4 FY2018: $46.0M · derived · 10-K 0001493594-19-000064 filed Nov 26, 2019Research and development · Q1 FY2019: $44.0M · 10-Q 0001493594-19-000008 filed Feb 6, 2019Research and development · Q2 FY2019: $42.0M · 10-Q 0001493594-19-000022 filed May 8, 2019Research and development · Q3 FY2019: $43.0M · 10-Q 0001493594-19-000051 filed Aug 6, 2019Research and development · Q4 FY2019: $35.0M · derived · 10-K 0001493594-20-000063 filed Nov 18, 2020Research and development · Q1 FY2020: $35.0M · 10-Q 0001493594-20-000017 filed Jan 29, 2020Research and development · Q2 FY2020: $36.0M · 10-Q 0001493594-20-000037 filed Apr 30, 2020Research and development · Q3 FY2020: $35.0M · 10-Q 0001493594-20-000051 filed Jul 30, 2020Research and development · Q4 FY2020: $35.0M · derived · 10-K 0001493594-21-000079 filed Nov 15, 2021Research and development · Q1 FY2021: $37.0M · 10-Q 0001493594-21-000014 filed Jan 28, 2021Research and development · Q2 FY2021: $35.0M · 10-Q 0001493594-21-000056 filed Apr 29, 2021Research and development · Q3 FY2021: $34.0M · 10-Q 0001493594-21-000072 filed Jul 29, 2021Research and development · Q4 FY2021: $34.0M · derived · 10-K 0001493594-22-000047 filed Nov 14, 2022Research and development · Q1 FY2022: $35.0M · 10-Q 0001493594-22-000011 filed Jan 27, 2022Research and development · Q2 FY2022: $35.0M · 10-Q 0001493594-22-000025 filed Apr 28, 2022Research and development · Q3 FY2022: $38.0M · 10-Q 0001493594-22-000037 filed Jul 28, 2022Research and development · Q4 FY2022: $40.0M · derived · 10-K 0001493594-23-000081 filed Nov 13, 2023Research and development · Q1 FY2023: $39.0M · 10-Q 0001493594-23-000035 filed Feb 2, 2023Research and development · Q2 FY2023: $36.0M · 10-Q 0001493594-23-000046 filed May 4, 2023Research and development · Q3 FY2023: $37.0M · 10-Q 0001493594-23-000057 filed Aug 3, 2023Research and development · Q4 FY2023: $38.0M · derived · 10-K 0001493594-24-000060 filed Nov 12, 2024Research and development · Q1 FY2024: $39.0M · 10-Q 0001493594-24-000028 filed Feb 1, 2024Research and development · Q2 FY2024: $46.0M · 10-Q 0001493594-24-000040 filed May 2, 2024Research and development · Q3 FY2024: $48.0M · 10-Q 0001493594-24-000052 filed Aug 1, 2024Research and development · Q4 FY2024: $50.0M · derived · 10-K 0001493594-25-000054 filed Nov 14, 2025Research and development · Q1 FY2025: $60.0M · 10-Q 0001493594-25-000020 filed Feb 6, 2025Research and development · Q2 FY2025: $58.0M · 10-Q 0001493594-25-000029 filed May 8, 2025Research and development · Q3 FY2025: $63.0M · 10-Q 0001493594-25-000038 filed Aug 7, 2025Research and development · Q4 FY2025: $63.0M · derived · 10-K 0001493594-25-000054 filed Nov 14, 2025Research and development · Q1 FY2026: $66.0M · 10-Q 0001493594-26-000019 filed Feb 5, 2026Research and development · Q2 FY2026: $69.0M · 10-Q 0001493594-26-000028 filed May 7, 2026Research and development · Q3 FY2026: $74.0M · 10-Q 0001493594-26-000038 filed Aug 6, 202626.274.3Q1 FY2016Q3 FY2026
$MResearch and development · Q1 FY2016: $25.0M · 10-Q 0001193125-16-439832 filed Jan 27, 2016Research and development · Q2 FY2016: $26.0M · 10-Q 0001193125-16-559543 filed Apr 27, 2016Research and development · Q3 FY2016: $26.0M · 10-Q 0001493594-16-000007 filed Jul 27, 2016Research and development · Q4 FY2016: $30.0M · derived · 10-K 0001493594-17-000055 filed Nov 15, 2017Research and development · Q1 FY2017: $30.0M · 10-Q 0001493594-17-000012 filed Feb 1, 2017Research and development · Q2 FY2017: $40.0M · 10-Q 0001493594-17-000037 filed Apr 26, 2017Research and development · Q3 FY2017: $39.0M · 10-Q 0001493594-17-000046 filed Aug 2, 2017Research and development · Q4 FY2017: $39.0M · derived · 10-K 0001493594-18-000034 filed Nov 16, 201826.239.4a25.339.7Q1 FY2016Q4 FY2017
Q2 FY2016
26.2$M
All values (43)
PeriodValue ($M)Status
Q3 FY202674.3reported
Q2 FY202669.0reported
Q1 FY202666.5reported
Q4 FY202562.9derived
Q3 FY202563.4reported
Q2 FY202557.8reported
Q1 FY202560.4reported
Q4 FY202449.6derived
Q3 FY202447.5reported
Q2 FY202445.6reported
Q1 FY202439.4reported
Q4 FY202337.5derived
Q3 FY202336.7reported
Q2 FY202335.5reported
Q1 FY202338.8reported
Q4 FY202239.7derived
Q3 FY202237.6reported
Q2 FY202235.5reported
Q1 FY202235.5reported
Q4 FY202133.7derived
Q3 FY202133.6reported
Q2 FY202134.6reported
Q1 FY202136.9reported
Q4 FY202035.4derived
Q3 FY202034.9reported
Q2 FY202035.8reported
Q1 FY202035.2reported
Q4 FY201934.9derived
Q3 FY201942.7reported
Q2 FY201942.4reported
Q1 FY201943.5reported
Q4 FY201846.2derived
Q3 FY201848.2reported
Q2 FY201841.6reported
Q1 FY201841.7reported
Q4 FY201739.4derived
Q3 FY201738.7reported
Q2 FY201739.7reported
Q1 FY201730.2reported
Q4 FY201630.1derived
Q3 FY201626.1reported
Q2 FY201626.2reported
Q1 FY201625.3reported

CSV with all sources · Technical ID: rnd

More metrics for MACOM

Income statement

Per share

Balance sheet

Cash flow

Debt and interest

Revenue by segment/product/region

Operating income by segment

Sources & calculation
Value
$26.0M
Period
Q2 FY2016, ended Apr 1, 2016 · quarterly value (3 months, not cumulative)
Source
10-Q, filed Apr 27, 2016 · 0001193125-16-559543
Location
us-gaap:ResearchAndDevelopmentExpense
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$26.0MApr 27, 201610-Q 0001193125-16-559543reported · confidence 1. · current